Youliang Ren, Jason Weeks, Thomas Xue, Joshua Rainbolt, Karen L de Mesy Bentley, Ye Shu, Yuting Liu, Elysia Masters, Philip Cherian, Charles E McKenna, Jeffrey Neighbors, Frank H Ebetino, Edward M Schwarz, Shuting Sun, Chao Xie
Eradication of MRSA osteomyelitis requires elimination of distinct biofilms. To overcome this, we developed bisphosphonate-conjugated sitafloxacin (BCS, BV600072) and hydroxybisphosphonate-conjugate sitafloxacin (HBCS, BV63072), which achieve "target-and-release" drug delivery proximal to the bone infection and have prophylactic efficacy against MRSA static biofilm in vitro and in vivo. Here we evaluated their therapeutic efficacy in a murine 1-stage exchange femoral plate model with bioluminescent MRSA (USA300LAC::lux)...
October 18, 2023: Bone Research